JP6770874B2 - Lactic acid bacteria count reduction inhibitor and fermented dairy products containing it - Google Patents

Lactic acid bacteria count reduction inhibitor and fermented dairy products containing it Download PDF

Info

Publication number
JP6770874B2
JP6770874B2 JP2016219089A JP2016219089A JP6770874B2 JP 6770874 B2 JP6770874 B2 JP 6770874B2 JP 2016219089 A JP2016219089 A JP 2016219089A JP 2016219089 A JP2016219089 A JP 2016219089A JP 6770874 B2 JP6770874 B2 JP 6770874B2
Authority
JP
Japan
Prior art keywords
lactic acid
banana
acid bacteria
fermented dairy
decrease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016219089A
Other languages
Japanese (ja)
Other versions
JP2018074950A (en
Inventor
有貴子 阿部
有貴子 阿部
中野 正理
正理 中野
大地 二瓶
大地 二瓶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yakult Honsha Co Ltd
Original Assignee
Yakult Honsha Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Co Ltd filed Critical Yakult Honsha Co Ltd
Priority to JP2016219089A priority Critical patent/JP6770874B2/en
Publication of JP2018074950A publication Critical patent/JP2018074950A/en
Application granted granted Critical
Publication of JP6770874B2 publication Critical patent/JP6770874B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Dairy Products (AREA)

Description

本発明は、光照射時の乳酸菌数低下抑制剤およびこれを含有する発酵乳製品に関する。 The present invention relates to an agent for suppressing a decrease in the number of lactic acid bacteria during light irradiation and a fermented dairy product containing the same.

近年、乳酸菌等の有用微生物がもつ様々な生理活性作用に関する研究がなされており、これらの微生物が腸内フローラを改善し、便通改善や免疫力の強化等の効果を有することが報告されている。そして、消費者の健康志向の高まりとともに、これらの有用微生物を利用した食品への関心も高まっており、発酵乳飲料やヨーグルトといった発酵乳製品は、これらの有用微生物を手軽に摂取することができるため、数多くの商品が販売されている。 In recent years, studies have been conducted on various physiologically active actions of useful microorganisms such as lactic acid bacteria, and it has been reported that these microorganisms have effects such as improving bowel flora, improving bowel movements and strengthening immunity. .. As consumers become more health conscious, interest in foods using these useful microorganisms is increasing, and fermented dairy products such as fermented milk drinks and yogurt can easily ingest these useful microorganisms. Therefore, many products are sold.

ところで、発酵乳製品の生理作用は、製品中の乳酸菌数に依存するところが多いため、乳酸菌の培養時において、増殖促進物質としてお茶のエキス、クロレラエキス、鉄塩等を添加しておくことが知られている。 By the way, since the physiological action of fermented dairy products often depends on the number of lactic acid bacteria in the product, it is known that tea extract, chlorella extract, iron salt, etc. are added as growth promoting substances when culturing lactic acid bacteria. Has been done.

しかしながら、製品を運搬したり販売を行う際、日光に照らされてしまったり、ショーケース内で連続して照明が当たったりするなど、長時間製品が光にさらされることがあり、このような場合、製品中に存在する菌の数が減少してしまうため、光照射下の環境においても、菌数の減少を抑制することが望まれていた。 However, when transporting or selling the product, the product may be exposed to light for a long time, such as being exposed to sunlight or being continuously illuminated in the showcase. Since the number of bacteria present in the product decreases, it has been desired to suppress the decrease in the number of bacteria even in an environment under light irradiation.

そして、これまで、本出願人は、光照射時であっても、菌数の低下を抑制するために、L−システイン塩酸塩やビタミンCなどの食品添加物を発酵乳製品中に添加することを報告している(特許文献1および特許文献2)。 So far, the applicant has added food additives such as L-cysteine hydrochloride and vitamin C to fermented dairy products in order to suppress a decrease in the number of bacteria even during light irradiation. (Patent Document 1 and Patent Document 2).

しかしながら、発酵乳製品中にL−システイン塩酸塩やビタミンCを添加することによって、光照射下における乳酸菌数の低下を抑制することはできたものの、近年の自然志向、健康志向により、食品添加物の摂取をなるべく回避したいという要望が消費者から求められていた。 However, although it was possible to suppress the decrease in the number of lactic acid bacteria under light irradiation by adding L-cysteine hydrochloride or vitamin C to fermented dairy products, it is a food additive due to recent nature and health consciousness. There was a demand from consumers to avoid the intake of lactic acid as much as possible.

特開2002−17254号公報Japanese Unexamined Patent Publication No. 2002-17254 特開2001−157547号公報Japanese Unexamined Patent Publication No. 2001-157547 特表2009−514519号公報Special Table 2009-514519

従って、本発明は、食品添加物ではなく、かつ、天然物由来のものを利用することによって、光にさらされる環境下において、乳酸菌数の低下を抑制する技術を提供することをその課題とするものである。 Therefore, it is an object of the present invention to provide a technique for suppressing a decrease in the number of lactic acid bacteria in an environment exposed to light by using a natural product rather than a food additive. It is a thing.

本発明者らは上記課題を解決するために鋭意研究した結果、バナナから得られたバナナ抽出物、バナナ果汁、バナナ抽出物の処理物およびバナナ果汁の処理物から選ばれる1種以上を有効成分として発酵乳中に添加することにより、光照射時における乳酸菌数の低下を抑制することを見出し、本発明を完成させた。 As a result of diligent research to solve the above problems, the present inventors have made one or more active ingredients selected from banana extract, banana juice, processed banana extract and processed banana juice obtained from bananas. By adding it to fermented milk, it was found that the decrease in the number of lactic acid bacteria during light irradiation was suppressed, and the present invention was completed.

すなわち、本発明は、以下の成分(A)〜(D):
(A)バナナ抽出物
(B)バナナ果汁
(C)バナナ抽出物の処理物
(D)バナナ果汁の処理物
から選ばれる1種以上を有効成分とすることを特徴とする光照射時の乳酸菌数低下抑制剤である。
That is, in the present invention, the following components (A) to (D):
(A) Banana extract (B) Banana juice (C) Processed banana extract (D) Number of lactic acid bacteria during light irradiation, characterized in that one or more selected from the processed banana juice is the active ingredient It is a decrease inhibitor.

また、本発明は上記乳酸菌数低下抑制剤と、乳酸菌とを含有する発酵乳製品である。 Further, the present invention is a fermented dairy product containing the above-mentioned lactic acid bacterium count reduction inhibitor and lactic acid bacteria.

更に、本発明は乳を主原料とする培地で乳酸菌を培養して乳酸菌培養物を調製し、次いで、この乳酸菌培養物に、以下の成分(A)〜(D):
(A)バナナ抽出物
(B)バナナ果汁
(C)バナナ抽出物の処理物
(D)バナナ果汁の処理物
から選ばれる1種以上を配合することを特徴とする発酵乳製品の製造方法である。
Further, in the present invention, lactic acid bacteria are cultivated in a medium containing milk as a main raw material to prepare a lactic acid bacterium culture, and then the following components (A) to (D):
A method for producing a fermented dairy product, which comprises blending one or more selected from (A) banana extract (B) banana juice (C) processed banana extract (D) processed banana juice. ..

また更に、本発明はバナナ抽出物またはバナナ果汁の透析処理液であって、バナナ抽出物またはバナナ果汁の分子量300Da以下の画分を含有する透析処理液である。 Furthermore, the present invention is a dialysis treatment solution for banana extract or banana juice, which contains a fraction of the banana extract or banana juice having a molecular weight of 300 Da or less.

また、本発明は上記透析処理液と、乳酸菌とを含有する発酵乳製品である。 Further, the present invention is a fermented dairy product containing the above dialysis treatment solution and lactic acid bacteria.

本発明の光照射時の乳酸菌数低下抑制剤は、光照射下において、乳酸菌の菌数の減少を抑制することができるものである。特に、本発明の光照射時の乳酸菌数低下抑制剤としてバナナ抽出物の処理物やバナナ果汁の処理物を用いた場合、これらを添加した発酵乳製品はバナナの風味があまり感じられないため、例えば、バナナ以外の果汁等を添加することによって、好みの風味に調整することが可能である。従って、本発明の光照射時の乳酸菌数低下抑制剤は、様々な発酵乳製品に利用することができるものである。 The agent for suppressing a decrease in the number of lactic acid bacteria during light irradiation of the present invention can suppress a decrease in the number of lactic acid bacteria under light irradiation. In particular, when a processed product of banana extract or a processed product of banana juice is used as the agent for suppressing the decrease in the number of lactic acid bacteria during light irradiation of the present invention, the fermented dairy product to which these are added does not have much banana flavor. For example, it is possible to adjust the flavor to a liking by adding fruit juice or the like other than banana. Therefore, the agent for suppressing a decrease in the number of lactic acid bacteria during light irradiation of the present invention can be used in various fermented dairy products.

また、本発明の光照射時の乳酸菌数低下抑制剤を添加した発酵乳製品は、運搬や陳列等の光にさらされる環境下において、菌数の低下が抑制されるため、健康の増進に役立つものである。 In addition, the fermented dairy product to which the agent for suppressing the decrease in the number of lactic acid bacteria during light irradiation of the present invention is added suppresses the decrease in the number of bacteria in an environment exposed to light such as transportation and display, which is useful for improving health. It is a thing.

本発明において、光とは、太陽光等の自然光や人工光源からの人工光を指し、光の波長は特に限定されない。人工光源の例としては、電球、ハロゲンランプ、アセチレンランプ、蛍光灯、高圧水銀灯、超高圧水銀灯、ナトリウム灯、キセノンランプ、メタルハライドランプ、ネオン灯、LED、レーザー等が挙げられる。また、本発明において記載されている光照射の照度(単位:ルクス)も特に限定されるものではない。 In the present invention, light refers to natural light such as sunlight or artificial light from an artificial light source, and the wavelength of light is not particularly limited. Examples of artificial light sources include light bulbs, halogen lamps, acetylene lamps, fluorescent lamps, high-pressure mercury lamps, ultra-high pressure mercury lamps, sodium lamps, xenon lamps, metal halide lamps, neon lamps, LEDs, lasers, and the like. Further, the illuminance (unit: lux) of light irradiation described in the present invention is not particularly limited.

本発明の光照射時の乳酸菌数低下抑制剤は乳酸菌の生菌数が減少することを抑制するものである。 The agent for suppressing a decrease in the number of lactic acid bacteria during light irradiation of the present invention suppresses a decrease in the viable number of lactic acid bacteria.

本発明の光照射時の乳酸菌数低下抑制剤(以下、「本発明抑制剤」という)の有効成分としては、成分(A)バナナ抽出物、成分(B)バナナ果汁、成分(C)バナナ抽出物の処理物および成分(D)バナナ果汁の処理物から選ばれる1種以上が使用される。 The active ingredients of the lactic acid bacterium count decrease inhibitor (hereinafter referred to as "the present invention inhibitor") of the present invention include component (A) banana extract, component (B) banana juice, and component (C) banana extract. Processed product and component (D) One or more selected from the processed product of banana juice is used.

本発明抑制剤を得る際に用いられるバナナ(バショウ科バショウ属に属する植物のうち、果実を食用とする植物)の品種としては、とくに制限されないが、例えばジャイアント・キャベンディッシュ、北蕉、グラネイン、モラード、島バナナ、セニョリータ、ラカタン、プランテイン等が挙げられ、これらを混合して使用することもできる。 The varieties of bananas (plants belonging to the genus Musaceae of the Musaceae family, whose fruits are edible) used to obtain the inhibitor of the present invention are not particularly limited, but are, for example, giant cavendish, northern banana, and granane. , Morado, island banana, senorita, lacatan, plantain, etc., and these can be mixed and used.

本発明抑制剤の有効成分となる成分(A)バナナ抽出物としては、例えば、バナナの樹皮、葉、果皮、果肉等の抽出物を挙げることができ、これら中でも、特に果肉の抽出物が好ましい。成分(A)バナナ抽出物の製造方法としては、特に限定されるものではないが、例えば、特表2009−514519号公報に記載の方法により容易に得ることができる。具体的には、例えば、皮を剥いたバナナ果肉に0.4倍量の水を加え、フードブレンダーで滑らかなペースト状となったものを、8000rpm、20分間遠心分離して、上清を得る。この上清をオートクレーブにて121℃、15分間滅菌し、さらに8000rpm、20分間遠心分離を行い、得られた上清をバナナ抽出物とする。 Examples of the component (A) banana extract that is the active ingredient of the inhibitor of the present invention include extracts such as banana bark, leaves, pericarp, and flesh, and among these, the extract of flesh is particularly preferable. .. The method for producing the banana extract of component (A) is not particularly limited, but it can be easily obtained by, for example, the method described in JP-A-2009-514519. Specifically, for example, 0.4 times the amount of water is added to the peeled banana pulp, and the smooth paste formed by a food blender is centrifuged at 8000 rpm for 20 minutes to obtain a supernatant. .. This supernatant is sterilized in an autoclave at 121 ° C. for 15 minutes, and further centrifuged at 8000 rpm for 20 minutes, and the obtained supernatant is used as a banana extract.

また、本発明抑制剤の有効成分となる成分(B)バナナ果汁としては、例えば、果肉や果皮の果汁を挙げることができ、これらの中でも、特に、果肉の果汁が好ましい。成分(B)バナナ果汁の製造方法としては、特に限定されるものではないが、例えば、皮を剥いたバナナ果肉を粉砕し、これにペクチナーゼやアミラーゼ等の酵素を添加して酵素処理を行い、ペクチンの分解が完了してペースト状になったものを濾過し、得られた濾過液をバナナ果汁とする。また、必要に応じて、バナナ果汁を脱水等して濃縮を行ってもよい。なお、バナナ果汁がフルクタ社やチキータ社等から上市されているため、これを用いることもできる。 In addition, examples of the component (B) banana juice that is the active ingredient of the inhibitor of the present invention include fruit juice of flesh and peel, and among these, fruit juice of flesh is particularly preferable. Ingredient (B) The method for producing banana juice is not particularly limited, but for example, peeled banana pulp is crushed, and an enzyme such as pectinase or amylase is added thereto for enzyme treatment. After the decomposition of pectin is completed, the paste is filtered, and the obtained filtrate is used as banana juice. If necessary, the banana juice may be dehydrated and concentrated. Since banana juice is marketed by Fructa, Chiquita, etc., it can also be used.

さらに、本発明抑制剤の有効成分となる成分(C)バナナ抽出物の処理物としては、上記成分(A)を用いて処理されたものであり、他方、成分(D)バナナ果汁の処理物としては、上記成分(B)を用いて処理されたものである。 Further, the processed product of the component (C) banana extract, which is the active ingredient of the inhibitor of the present invention, is the one treated with the above component (A), while the processed product of the component (D) banana juice. Is processed using the above component (B).

上記成分(C)及び成分(D)の処理物としては、例えば、膜分離によって得られた透析処理液、加熱処理により得られた加熱物、蒸留により得られた蒸留物、沈殿物を除去して得られた上澄み液、ろ過によって得られたろ液等が挙げられ、これらの中でも、特に膜分離によって得られた透析処理液が好ましい。膜分離によって得られた透析処理液としては、例えば、セロファン膜等の半透膜で処理した半透膜透析処理液や、イオン交換膜で処理した電気透析処理液が挙げられ、これらの中でも、電気透析処理液が好ましい。この電気透析処理液としては、電気透析処理により得られる濃縮液(以下、「電気透析処理透過液」ともいう)および脱塩液が挙げられ、いずれも本発明抑制剤の有効成分として使用することができるが、この中でも、特に電気透析処理透過液が好ましい。電気透析処理透過液は下記電気透析装置に使用する分離膜によって、電気透析処理透過液中の分子量を調節することができるが、分子量300Da以下の画分を含むものが好ましい。 As the treated product of the above component (C) and the component (D), for example, a dialysis treatment solution obtained by membrane separation, a heated product obtained by heat treatment, a distilled product obtained by distillation, and a precipitate are removed. Examples thereof include the supernatant obtained from the above, the filtrate obtained by filtration, and the like, and among these, the dialysis treatment solution obtained by membrane separation is particularly preferable. Examples of the dialysis treatment solution obtained by membrane separation include a semipermeable membrane dialysis treatment solution treated with a semipermeable membrane such as a cellophane membrane, and an electrodialysis treatment liquid treated with an ion exchange membrane. An electrodialysis treatment solution is preferable. Examples of this electrodialysis treatment solution include a concentrate obtained by electrodialysis treatment (hereinafter, also referred to as “electrodialysis treatment permeate”) and a desalting solution, both of which are used as the active ingredient of the inhibitor of the present invention. Of these, an electrodialysis-treated permeate is particularly preferable. The molecular weight of the electrodialysis-treated permeate can be adjusted by the separation membrane used in the following electrodialysis apparatus, but those containing a fraction having a molecular weight of 300 Da or less are preferable.

ここで、電気透析に使用される電気透析処理装置としては、例えば、陰極と陽極の間が複数の陽イオン交換膜と陰イオン交換膜により交互に仕切られ、陰極室、陽極室、複数の脱塩室および複数の濃縮室を備えるもの等が挙げられる。このような電気透析処理装置では、イオン性の物質が濃縮された液(濃縮液)と、イオン性の物質が除去された液(脱塩液)が得られる。すなわち、陽極側にある陽イオン交換膜と陰極側にある陰イオン交換膜で仕切られた部分が濃縮室であり、濃縮室に還流している液体が濃縮液である。そして陽極側にある陰イオン交換膜と陰極側にある陽イオン交換膜とで仕切られた部分が脱塩室であり、脱塩室に還流している液体が脱塩液である。電気透析処理装置は、マイクロアシライザーS3(株式会社アストム社製)等の名称で市販もされているため、これらを利用することもできる。 Here, as the electrodialysis treatment apparatus used for electrodialysis, for example, the cathode and the anode are alternately partitioned by a plurality of cation exchange membranes and anion exchange membranes, and the cathode chamber, the anode chamber, and the plurality of desorption are performed. Examples include those having a salt chamber and a plurality of concentration chambers. In such an electrodialysis treatment apparatus, a liquid in which an ionic substance is concentrated (concentrated liquid) and a liquid in which the ionic substance is removed (desalted liquid) can be obtained. That is, the portion partitioned by the cation exchange membrane on the anode side and the anion exchange membrane on the cathode side is the concentration chamber, and the liquid returning to the concentration chamber is the concentrate. The portion partitioned by the anion exchange membrane on the anode side and the cation exchange membrane on the cathode side is the desalting chamber, and the liquid returning to the desalting chamber is the desalting liquid. Since the electrodialysis treatment apparatus is commercially available under the name of Microacylizer S3 (manufactured by Astom Co., Ltd.), these can also be used.

上記電気透析処理透過液及び上記脱塩液を得るための具体的な方法としては、電気透析処理装置の脱塩室に、例えば、上記成分(A)または上記成分(B)をそのまま又は、脱イオン水等で希釈したものを還流し、濃縮室に水等を還流して電気透析処理を行うことが挙げられる。 As a specific method for obtaining the electrodialysis treatment permeate and the desalting solution, for example, the component (A) or the component (B) is left as it is or removed in the desalting chamber of the electrodialysis treatment apparatus. An example is to perform electrodialysis treatment by refluxing a product diluted with ionized water or the like and refluxing water or the like to a concentration chamber.

上記電気透析の条件は特に制限されるものではないが、例えば、濃縮室に成分(A)または成分(B)の5〜100質量%(以下、単に「%」という)相当量、好ましくは10〜60%相当量の水を還流して陰極と陽極の間に10〜200Vの電圧をかけ電流を通じて、脱塩室の電気伝導度が平衡(0ミリジーメンス毎センチメートル(mS/cm))となるまで電気透析処理を行い、濃縮液を回収することにより得る方法を挙げることができる。濃縮室に還流させる液体は、水以外にも例えば、食塩水、クエン酸水等の電解質溶液も使用することができる。 The conditions of the above electrodialysis are not particularly limited, but for example, an amount equivalent to 5 to 100% by mass (hereinafter, simply referred to as "%") of the component (A) or the component (B) in the concentration chamber, preferably 10. The electric conductivity of the desalting chamber is balanced (0 millisiemens per centimeter (mS / cm)) by circulating a voltage of 10 to 200 V between the cathode and the anode by refluxing an amount of water equivalent to ~ 60%. Examples thereof include a method obtained by performing electrodialysis treatment until it becomes possible and collecting the concentrated solution. As the liquid to be refluxed to the concentration chamber, for example, an electrolyte solution such as saline solution or citric acid water can be used in addition to water.

本発明抑制剤は、上記のようにして得られた成分(A)〜成分(D)から選ばれる1種以上をそのままの状態で使用しても、また、これらを更に噴霧乾燥や凍結乾燥等の手段により乾燥させた粉末状で使用してもよい。本発明抑制剤を、通常発酵乳製品に添加することが認められている他の副素材と併せて発酵乳中に配合することにより、発酵乳製品が得られる。 In the inhibitor of the present invention, one or more selected from the components (A) to (D) obtained as described above can be used as they are, or these can be further spray-dried, freeze-dried, etc. It may be used in the form of a powder dried by the above means. A fermented dairy product can be obtained by blending the inhibitor of the present invention in fermented milk together with other auxiliary materials that are normally approved to be added to fermented dairy products.

本発明抑制剤を発酵乳製品に添加するにあたっての添加量は、特に制限されないが、例えば、0.1〜10質量%(以下、単に「%」で示す)が好ましく、0.5〜2%がより好ましく、0.5〜1%が特に好ましい。具体的には、成分(A)を有効成分とする場合0.1〜10%が好ましく、0.5〜2%がより好ましく、0.5〜1%が特に好ましい。また、成分(B)を有効成分とする場合0.1〜10%が好ましく、0.5〜2%がより好ましく、0.5〜1%が特に好ましい。さらに、成分(C)を有効成分とする場合0.07〜7.3%が好ましく、0.37〜1.46%がより好ましく、0.37〜0.73%が特に好ましい。またさらに、成分(D)を有効成分とする場合0.07〜7.3%が好ましく0.37〜1.46%がより好ましく、0.37〜0.73%が特に好ましい。 The amount of the inhibitor of the present invention added to the fermented dairy product is not particularly limited, but is preferably 0.1 to 10% by mass (hereinafter, simply indicated by "%"), and is 0.5 to 2%. Is more preferable, and 0.5 to 1% is particularly preferable. Specifically, when the component (A) is used as an active ingredient, 0.1 to 10% is preferable, 0.5 to 2% is more preferable, and 0.5 to 1% is particularly preferable. When the component (B) is used as an active ingredient, 0.1 to 10% is preferable, 0.5 to 2% is more preferable, and 0.5 to 1% is particularly preferable. Further, when the component (C) is used as an active ingredient, 0.07 to 7.3% is preferable, 0.37 to 1.46% is more preferable, and 0.37 to 0.73% is particularly preferable. Furthermore, when the component (D) is used as an active ingredient, 0.07 to 7.3% is preferable, 0.37 to 1.46% is more preferable, and 0.37 to 0.73% is particularly preferable.

なお、本発明抑制剤の発酵乳製品への添加時期は、乳酸菌の培養終了後であることが好ましいが、これに限らず、乳酸菌を培養する前でも、培養の途中で加えてもよい。また、複数回に分けて加えることも可能である。特に、本発明抑制剤を乳酸菌培養終了後に得られる乳酸菌培養物に添加すると、光照射時における乳酸菌数の低下を強く抑制することができる。 The time for adding the inhibitor of the present invention to the fermented dairy product is preferably after the completion of culturing the lactic acid bacterium, but the present invention is not limited to this, and the inhibitor may be added before or during the culturing of the lactic acid bacterium. It is also possible to add it in multiple times. In particular, when the inhibitor of the present invention is added to the lactic acid bacterium culture obtained after the lactic acid bacterium culture is completed, the decrease in the number of lactic acid bacteria during light irradiation can be strongly suppressed.

ここで、発酵乳製品とは、発酵豆乳若しくは乳等省令により定められている発酵乳、乳製品乳酸菌飲料等の飲料やハードヨーグルト、ソフトヨーグルト、プレーンヨーグルト、更にはケフィア、チーズ等も包含するものである。また、本発明の発酵乳製品には、種々の乳酸菌を利用した飲食品、例えば、プレーンタイプ、フレーバードタイプ、フルーツタイプ、甘味タイプ、ソフトタイプ、ドリンクタイプ、固形(ハード)タイプ、フローズンタイプ等の発酵乳、乳酸菌飲料、ケフィア、チーズ等が含まれる。 Here, the fermented dairy products include fermented soybean milk, fermented milk specified by the Ordinance of the Ministry of Milk, etc., beverages such as dairy lactic acid bacteria beverages, hard yogurt, soft yogurt, plain yogurt, kefir, cheese and the like. Is. Further, the fermented dairy product of the present invention includes foods and drinks using various lactic acid bacteria, for example, plain type, flavored type, fruit type, sweet type, soft type, drink type, solid (hard) type, frozen type and the like. Fermented milk, lactic acid bacteria beverage, kefir, cheese, etc. are included.

これらの発酵乳製品は、上記した乳酸菌培養物に必要に応じて、シロップ等の甘味料のほか、それ以外の各種食品素材、例えば、各種糖質、増粘剤、乳化剤、各種ビタミン剤等の任意成分を配合することにより得られる。これらの食品素材として具体的なものは、ショ糖、グルコース、フルクトース、パラチノース、トレハロース、ラクトース、キシロース、麦芽糖等の糖質、ソルビトール、キシリトール、エリスリトール、ラクチトール、パラチニット、還元水飴、還元麦芽糖水飴等の糖アルコール、アスパルテーム、ソーマチン、スクラロース、アセスルファムK、ステビア等の高甘味度甘味料、寒天、ゼラチン、カラギーナン、グァーガム、キサンタンガム、ペクチン、ローカストビーンガム、ジェランガム、カルボキシメチルセルロース、大豆多糖類、アルギン酸プロピレングリコール等の各種増粘(安定)剤、ショ糖脂肪酸エステル、グリセリン脂肪酸エステル、ポリグリセリン脂肪酸エステル、ソルビタン脂肪酸エステル、レシチン等の乳化剤、クリーム、バター、サワークリームなどの乳脂肪、クエン酸、乳酸、酢酸、リンゴ酸、酒石酸、グルコン酸等の酸味料、ビタミンA、ビタミンB類、ビタミンC、ビタミンE類等の各種ビタミン類、カルシウム、マグネシウム、亜鉛、鉄、マンガン等のミネラル分、ヨーグルト系、ベリー系、オレンジ系、花梨系、シソ系、シトラス系、アップル系、ミント系、グレープ系、アプリコット系、ペア、カスタードクリーム、ピーチ、メロン、バナナ、トロピカル系、ハーブ系、紅茶、コーヒー系等のフレーバー類を挙げることができる。 These fermented dairy products include sweeteners such as syrup and other food materials such as various sugars, thickeners, emulsifiers, and various vitamins, as required for the above-mentioned lactic acid bacteria culture. Obtained by blending arbitrary ingredients. Specific examples of these food materials include sugars such as sucrose, glucose, fructose, carrageenan, trehalose, lactose, xylose, and malt sugar, sorbitol, xylitol, erythritol, lactitol, palatinit, reduced water candy, and reduced malt sugar water candy. High-sweetness sweeteners such as sugar alcohols, aspartame, somatine, sucralose, assesulfam K, stevia, agar, gelatin, carrageenan, guar gum, xanthan gum, pectin, locust bean gum, gellan gum, carboxymethyl cellulose, soybean polysaccharide, propylene glycol alginate, etc. Various thickeners (stabilizers), sucrose fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, sorbitol fatty acid ester, emulsifiers such as lecithin, milk fat such as cream, butter, sour cream, citric acid, lactic acid, acetic acid, apple Acidulants such as acid, tartrate, gluconic acid, various vitamins such as vitamin A, vitamin B, vitamin C, vitamin E, minerals such as calcium, magnesium, zinc, iron, manganese, yogurt, berry, etc. Flavors such as orange, carrageenan, perilla, citrus, apple, mint, grape, apricot, pair, custard cream, peach, melon, banana, tropical, herb, tea, coffee, etc. Can be mentioned.

また、上記発酵乳製品を得るために、培養される乳酸菌としては、通常、食品製造に使用される乳酸菌であれば特に限定されず、例えば、ラクトバチルス・カゼイ(Lactobacillus casei)、ラクトバチルス・パラカゼイ(Lactobacillus paracasei)、ラクトバチルス・ガセリ(Lactobacillus gasseri)、ラクトバチルス・アシドフィルス(Lactobacillus acidophilus)、ラクトバチルス・クレモリス(Lactobacillus cremoris)、ラクトバチルス・ヘルベティカス(Lactobacillus helveticus)、ラクトバチルス・サリバリウス(Lactobacillus salivarius)、ラクトバチルス・ファーメンタム(Lactobacillus fermentum)、ラクトバチルス・ユーグルティ(Lactobacillus yoghurti)、ラクトバチルス・デルブルッキィー サブスピーシーズ.ブルガリカス(Lactobacillus delbrueckii subsp. bulgaricus)、ラクトバチルス・デルブルッキィー サブスピーシーズ.デルブルッキィー(Lactobacillus delbrueckii subsp. delbrueckii)、ラクトバチルス・ジョンソニー(Lactobacillus johnsonii)等のラクトバチルス属細菌、ストレプトコッカス・サーモフィルス(Streptococcus thermophilus)等のストレプトコッカス属細菌、ラクトコッカス・ラクチス サブスピーシーズ.ラクチス(Lactococcus lactis subsp. lactis)、ラクトコッカス・ラクチス サブスピーシーズ.クレモリス(Lactococcus lactis subsp. cremoris)、ラクトコッカス・プランタラム(Lactococcus plantarum)、ラクトコッカス・ラフィノラクチス(Lactococcus raffinolactis)等のラクトコッカス属細菌、エンテロコッカス・フェカリス(Enterococcus faecalis)、エンテロコッカス・フェシウム(Enterococcus faecium)等のエンテロコッカス属細菌、ビフィドバクテリウム・ブレーベ(Bifidobacterium breve)、ビフィドバクテリウム・ロンガム(Bifidobacterium longum)、ビフィドバクテリウム・インファンティス(Bifidobacterium infantis)、ビフィドバクテリウム・アドレスセンティス(Bifidobacterium adolescentis)、ビフィドバクテリウム・ビフィダム(Bifidobacterium bifidum)、ビフィドバクテリウム・カテヌラータム(Bifidobacterium catenulatum)、ビフィドバクテリウム・シュードカテヌラータム(Bifidobacterium pseudocatenulatum)、ビフィドバクテリウム・アングラータム(Bifidobacterium angulatum)等のビフィドバクテリウム属細菌を挙げることができる。これらの乳酸菌の中でもラクトバチルス属細菌が好ましく、これらの中でもラクトバチルス・カゼイまたはラクトバチルス・ガセリがより好ましく、特にラクトバチルス・カゼイYIT9029(FERM BP−1366、受託日:昭和56年1月12日、独立行政法人産業技術総合研究所特許生物寄託センター(〒305-8566日本国茨城県つくば市東1丁目1番地1中央第6))が好ましい。 The lactic acid bacterium to be cultivated to obtain the fermented dairy product is not particularly limited as long as it is a lactic bacterium usually used for food production. For example, Lactobacillus casei, Lactobacillus casei, Lactobacillus casei, etc. (Lactobacillus paracasei), Lactobacillus gasseri, Lactobacillus acidophilus, Lactobacillus cremoris, Lactobacillus helveticus, Lactobacillus helveticus, Lactobacillus helveticus Lactobacillus fermentum, Lactobacillus yoghurti, Lactobacillus yoghurti, Lactobacillus subspecies. Bulgaricus (Lactobacillus delbrueckii subsp. Bulgaricus), Lactobacillus delbrueckii subspice. Lactobacillus delbrueckii subsp. Delbrueckii, Lactobacillus johnsonii and other Lactobacillus bacteria, Streptococcus thermophilus and other Streptococcus thermophilus, and Lactobacillus subsp. Lactobacillus subsp. Lactococcus lactis subsp. Lactis, Lactococcus lactis subsp. Lactis. Bifidobacterium genus Lactococcus lactis subsp. Cremoris, Lactococcus plantarum, Lactococcus raffinolactis, Enterococcus faecalis, Enterococcus faecalis, Enterococcus faecalis, Enterococcus faecalis Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium addresscentis, etc. adolescentis), Bifidobacterium bifidum, Bifidobacterium catenulatum, Bifidobacterium pseudocatenulatum, Bifidobacterium angulatum Bifidobacterium spp. And other bacteria can be mentioned. Among these lactic acid bacteria, Lactobacillus bacteria are preferable, and among these, Lactobacillus casei or Lactobacillus gasseri is more preferable, and in particular, Lactobacillus casei YIT9029 (FERM BP-1366, consignment date: January 12, 1981). , Independent Administrative Institution Industrial Technology Research Institute Patent Organism Depositary Center (1-1-1, Higashi-1-1, Tsukuba-shi, Ibaraki-shi, Japan 305-8566, Central 6th) is preferable.

また、上記発酵乳製品を得るために、乳酸菌を培養する培養条件は特に限定されないが、例えば、乳を主原料とする培地に乳酸菌を、培地中の菌数が1.0×10〜1.0×10cfu/ml程度となるように接種し、これを30〜40℃程度の温度で1〜7日間程度培養する条件が挙げられる。また、このときの培養条件としては、静置、攪拌、振盪、通気等から用いる乳酸菌の培養に適した方法を適宜選択して行えばよい。 Further, in order to obtain the fermented milk product, although culture conditions for culturing lactic acid bacteria is not particularly limited, for example, lactic acid bacteria in medium containing milk as a main raw material, the number of bacteria in the culture medium 1.0 × 10 3 to 1 Conditions include inoculation at a temperature of about .0 × 10 9 cfu / ml and culturing this at a temperature of about 30 to 40 ° C. for about 1 to 7 days. Further, as the culture conditions at this time, a method suitable for culturing the lactic acid bacteria used from standing, stirring, shaking, aeration, etc. may be appropriately selected.

斯くして得られる本発明抑制剤を含有する発酵乳製品は、光照射下で保存された場合に、乳酸菌数の低下を抑制することができるものである。 The fermented dairy product containing the inhibitor of the present invention thus obtained can suppress a decrease in the number of lactic acid bacteria when stored under light irradiation.

なお、従来から、乳酸菌の増殖を促進させるために、バナナ抽出物を培地に添加して培養することが知られている(特許文献3)。しかしながら、本発明抑制剤は、このような乳酸菌の増殖を高めるといった発想では全くなく、光照射が原因となる乳酸菌数の低下を抑制するというものであるため、バナナ抽出物による乳酸菌の増殖促進作用とは異なった技術思想に基づくものである。なお、本発明抑制剤は、遮光時における乳酸菌数の低下を抑制するという効果を奏するものではなく、光照射時に限り有効なものである。 It has been conventionally known that a banana extract is added to a medium and cultured in order to promote the growth of lactic acid bacteria (Patent Document 3). However, the inhibitor of the present invention does not have the idea of increasing the growth of lactic acid bacteria at all, but suppresses the decrease in the number of lactic acid bacteria caused by light irradiation. Therefore, the banana extract promotes the growth of lactic acid bacteria. It is based on a different technical idea. The inhibitor of the present invention does not have the effect of suppressing a decrease in the number of lactic acid bacteria during shading, but is effective only during light irradiation.

以下、実施例を挙げて本発明を詳細に説明するが、本発明はこれら実施例に何ら限定されるものではない。 Hereinafter, the present invention will be described in detail with reference to examples, but the present invention is not limited to these examples.

製 造 例 1
バナナ果汁の電気透析処理透過液及び脱塩液の製造(1):
濃縮バナナ果汁(Brix68.2)を脱イオン水で5倍希釈し、これを電気透析処理装置(膜カートリッジ:AC−220−550、分画分子量300Da、製品名:マイクロアシライザーS3、装置メーカー:株式会社アストム社製)の脱塩室に500g入れた。なお、濃縮バナナ果汁の5倍希釈液のBrixは13.9であった。濃縮室には、300gの脱イオン水を入れた。電極液には5%硫酸ナトリウム水溶液を用いて、脱塩室の電気伝導度が平衡となるまで8時間程度、電気透析処理を行い、脱塩液(Brix13.9)と濃縮液(Brix1.9)に分離した。この濃縮液を、バナナ果汁の電気透析処理透過液とした。
Manufacturing example 1
Production of electrodialysis permeate and desalting solution for banana juice (1):
Concentrated banana juice (Brix68.2) was diluted 5-fold with deionized water, and this was diluted with an electrodialysis treatment device (membrane cartridge: AC-220-550, molecular weight cut-off 300 Da, product name: Microacylizer S3, device manufacturer: 500 g was put into the desalting chamber of Astom Co., Ltd.). The Brix of the 5-fold diluted solution of concentrated banana juice was 13.9. 300 g of deionized water was placed in the concentration chamber. Using a 5% aqueous sodium sulfate solution as the electrode solution, electrodialysis treatment was performed for about 8 hours until the electrical conductivity of the desalting chamber became equilibrium, and then the desalted solution (Brix13.9) and the concentrated solution (Brix1.9) were subjected to electrodialysis treatment. ). This concentrated solution was used as an electrodialysis-treated permeate of banana juice.

ここでBrix値は、20℃のショ糖溶液の質量百分率に相当する値であり、Brix屈折計で測定される糖度であって、固形分濃度の目安となる値である。 Here, the Brix value is a value corresponding to the mass percentage of the sucrose solution at 20 ° C., which is the sugar content measured by the Brix refractometer and is a value that serves as a guide for the solid content concentration.

製 造 例 2
バナナ抽出物の製造:
皮を剥いたバナナ果肉250gと水100mLをフードブレンダーに入れ、滑らかなペースト状にした。このペーストを8000rpm、20分間遠心分離を行い、上清を得た。上清をオートクレーブにて121℃、15分間滅菌し、さらに8000rpm、20分間遠心分離を行った。得られた上清をバナナ抽出物(Brix17)とした。
Manufacturing example 2
Banana extract production:
250 g of peeled banana pulp and 100 mL of water were placed in a food blender to form a smooth paste. The paste was centrifuged at 8000 rpm for 20 minutes to obtain a supernatant. The supernatant was sterilized in an autoclave at 121 ° C. for 15 minutes, and further centrifuged at 8000 rpm for 20 minutes. The obtained supernatant was used as a banana extract (Brix17).

試 験 例 1
光照射保存における乳酸菌数低下抑制試験:
10%脱脂粉乳培地を基本培地とし、100℃、15分間加熱殺菌して培養培地を調整した。この培地にラクトバチルス・カゼイ(YIT9029)のスターターを0.1%接種して(初発菌数:1.5×10cfu/ml)、37℃で24時間培養を行い、乳酸菌培養物を得た。この乳酸菌培養物にシロップおよび水を加え、さらに、製造例1で得られた電気透析処理透過液(Brix1.9)を乳酸菌飲料に対して0.73%となるよう添加して乳酸菌飲料を調製した。この乳酸菌飲料を実施例1とした。
Trial example 1
Test to suppress decrease in lactic acid bacteria count in light irradiation storage:
Using 10% skim milk powder as the basal medium, the culture medium was prepared by heat sterilization at 100 ° C. for 15 minutes. This medium was inoculated with 0.1% of a starter of Lactobacillus casei (YIT9029) (initial number of bacteria: 1.5 × 10 6 cfu / ml) and cultured at 37 ° C. for 24 hours to obtain a lactic acid bacterium culture. It was. Syrup and water are added to this lactic acid bacterium culture, and the electrodialysis treatment permeate (Brix 1.9) obtained in Production Example 1 is further added so as to be 0.73% with respect to the lactic acid bacterium beverage to prepare a lactic acid bacterium beverage. did. This lactic acid bacteria beverage was designated as Example 1.

また、濃縮バナナ果汁の水希釈液(Brix17)を乳酸菌飲料に対して1%となるよう添加することに変更する以外は、実施例1と同様の方法により乳酸菌飲料を調製し、これを実施例2とした。 In addition, a lactic acid bacterium beverage was prepared by the same method as in Example 1 except that a water-diluted solution of concentrated banana juice (Brix17) was added to the lactic acid bacterium beverage so as to be 1%. It was set to 2.

さらに、バナナ抽出物(Brix17)を乳酸菌飲料に対して1%となるよう添加することに変更する以外は、実施例1と同様の方法により乳酸菌飲料を調製し、これを実施例3とした。 Further, a lactic acid bacterium beverage was prepared by the same method as in Example 1 except that the banana extract (Brix17) was added so as to be 1% with respect to the lactic acid bacterium beverage, and this was designated as Example 3.

また、製造例1で得られた脱塩液(Brix13.9)を乳酸菌飲料に対して1.22%となるよう添加することに変更する以外は、実施例1と同様の方法により乳酸菌飲料を調製し、これを実施例4とした。 Further, the lactic acid bacteria beverage is prepared by the same method as in Example 1 except that the desalting solution (Brix13.9) obtained in Production Example 1 is added so as to be 1.22% with respect to the lactic acid bacteria beverage. It was prepared and designated as Example 4.

一方、バナナの成分を含まないことに変更する以外は、実施例1と同様の方法により乳酸菌飲料を調製し、これを比較例1とした。 On the other hand, a lactic acid bacterium beverage was prepared by the same method as in Example 1 except that the banana component was not contained, and this was designated as Comparative Example 1.

実施例1〜4および比較例1の乳酸菌飲料を光安定性試験機(1200ルクス、10℃の環境条件、製品名:プログラム光安定性試験機LST−2000、装置メーカー:東京理化器械株式会社)内に保存し、保存開始直後と、保存後7日後の生菌数を希釈平板法により測定した。また、この乳酸菌飲料中の菌の生残率((a))を以下の式[数1]により求めた。さらに、乳酸菌飲料への各バナナ成分の添加量とそのBrixから、乳酸菌飲料中のバナナの成分由来のBrix((b))と乳酸菌飲料中の単位固形分濃度(Brix1)あたりの生残率(理論値)((c))を求めた。 Photostability tester for lactic acid bacteria beverages of Examples 1 to 4 and Comparative Example 1 (1200 lux, 10 ° C. environmental conditions, product name: Program photostability tester LST-2000, device manufacturer: Tokyo Rika Kikai Co., Ltd.) The viable cell count was measured immediately after the start of storage and 7 days after storage by the dilution plate method. In addition, the survival rate ((a)) of the bacteria in this lactic acid bacteria beverage was calculated by the following formula [Equation 1]. Furthermore, from the amount of each banana component added to the lactic acid bacteria beverage and its Brix, the Brix ((b)) derived from the banana component in the lactic acid bacteria beverage and the survival rate per unit solid content concentration (Brix 1) in the lactic acid bacteria beverage (Brix 1) The theoretical value) ((c)) was obtained.

Figure 0006770874
Figure 0006770874

また、さらに、乳酸菌飲料の保存開始直後の風味を下記評価基準により評価した。結果を表1に示す。 Furthermore, the flavor of the lactic acid bacteria beverage immediately after the start of storage was evaluated according to the following evaluation criteria. The results are shown in Table 1.

<風味評価基準>
評点:内容
5:バナナの風味はしない。
4:バナナの風味がほとんどない。
3:バナナの風味がやや感じられる。
2:バナナの風味が感じられる。
1:バナナの風味が強く感じられる。
<Flavor evaluation criteria>
Score: Content 5: No banana flavor.
4: There is almost no banana flavor.
3: The banana flavor is slightly felt.
2: You can feel the flavor of banana.
1: The banana flavor is strongly felt.

Figure 0006770874
Figure 0006770874

表1から明らかなように、電気透析処理透過液を添加した実施例1、バナナ果汁を添加した実施例2、バナナ抽出物を添加した実施例3及び脱塩液を添加した実施例4は、無添加の乳酸菌飲料である比較例1と比べて生残率が高く、光照射下の保存において、乳酸菌数の減少が抑制される効果が確認された。特に、電気透析処理透過液を添加した実施例1は、Brix1あたりの生残率改善効果が最も高く、光照射時の乳酸菌数低下抑制効果が極めて優れていた。 As is clear from Table 1, Example 1 to which the electrodialysis treatment permeate was added, Example 2 to which the banana juice was added, Example 3 to which the banana extract was added, and Example 4 to which the desalted solution was added were shown. Compared with Comparative Example 1, which is an additive-free lactic acid bacterium beverage, the survival rate was higher, and it was confirmed that the effect of suppressing the decrease in the number of lactic acid bacteria was suppressed when stored under light irradiation. In particular, Example 1 to which the electrodialysis treatment permeate was added had the highest effect of improving the survival rate per Brix 1, and was extremely excellent in the effect of suppressing a decrease in the number of lactic acid bacteria during light irradiation.

さらに、電気透析処理透過液を添加した実施例1は、乳酸菌飲料中のバナナの成分由来のBrixが低いにも関わらず、光照射時の乳酸菌数低下抑制効果が高く、バナナの風味はほとんど感じられなかった。このため、電気透析処理透過液は、バナナ以外の果汁等を添加して好みの風味に調製が可能であるため、使用性が良いことが確認された。 Further, in Example 1 in which the electrodialysis treatment permeate was added, although the Brix derived from the banana component in the lactic acid bacteria beverage was low, the effect of suppressing the decrease in the number of lactic acid bacteria during light irradiation was high, and the banana flavor was almost felt. I couldn't. Therefore, it was confirmed that the electrodialysis-treated permeate has good usability because it can be prepared to have a desired flavor by adding fruit juice or the like other than banana.

製 造 例 3
バナナ果汁の電気透析処理透過液及び脱塩液の製造(2):
濃縮バナナ果汁(Brix68.2)を脱イオン水で5倍希釈し、これを電気透析処理装置(膜カートリッジ:AC−220−550、分画分子量300Da、製品名:マイクロアシライザーS3、装置メーカー:株式会社アストム社製)の脱塩室に500g入れた。なお、濃縮バナナ果汁の5倍希釈液のBrixは12.3であった。濃縮室には、300gの脱イオン水を入れた。電極液には5%硫酸ナトリウム水溶液を用いて、脱塩室の電気伝導度が平衡となるまで8時間程度、電気透析処理を行い、脱塩液(Brix12.3)と濃縮液(Brix0.87)に分離した。この濃縮液を、バナナ果汁の電気透析処理透過液とした。
Manufacturing example 3
Production of electrodialysis permeate and desalting solution for banana juice (2):
Concentrated banana juice (Brix68.2) was diluted 5-fold with deionized water, and this was diluted with an electrodialysis treatment device (membrane cartridge: AC-220-550, molecular weight cut-off 300 Da, product name: Microacylizer S3, device manufacturer: 500 g was put into the desalting chamber of Astom Co., Ltd.). The Brix of the 5-fold diluted solution of concentrated banana juice was 12.3. 300 g of deionized water was placed in the concentration chamber. Using a 5% aqueous sodium sulfate solution as the electrode solution, electrodialysis treatment was performed for about 8 hours until the electrical conductivity of the desalting chamber became equilibrium, and then the desalted solution (Brix12.3) and the concentrated solution (Brix0.87) were subjected to electrodialysis treatment. ). This concentrated solution was used as an electrodialysis-treated permeate of banana juice.

参 考 試 験1:
遮光保存における乳酸菌数低下抑制試験:
10%脱脂粉乳培地を基本培地とし、これに製造例3で得られた電気透析透過液(Brix0.87)を1.82%となるように添加し、100℃、15分間加熱殺菌して培養培地を調整した。この培養培地にラクトバチルス・カゼイ(YIT9029)のスターターを0.1%接種して(初発菌数:1.5×10cfu/ml)、37℃で24時間培養を行い、乳酸菌培養物を得た。この乳酸菌培養物にシロップおよび水を加えて、電気透析処理透過液を0.41%含有する乳酸菌飲料(試験品1)を調製した。
Examination Examination 1:
Test to suppress decrease in lactic acid bacteria count in light-shielded storage:
Using 10% skim milk powder as the basic medium, add the electrodialysis permeate (Brix 0.87) obtained in Production Example 3 to 1.82%, heat sterilize at 100 ° C for 15 minutes, and incubate. The medium was adjusted. 0.1% of Lactobacillus casei (YIT9029) starter was inoculated into this culture medium (initial number of bacteria: 1.5 × 10 6 cfu / ml), and the cells were cultured at 37 ° C. for 24 hours to prepare a lactic acid bacterium culture. Obtained. Syrup and water were added to this lactic acid bacterium culture to prepare a lactic acid bacterium beverage (test product 1) containing 0.41% of an electrodialysis treatment permeate.

さらに、濃縮バナナ果汁の水希釈液(Brix17)を培地に2.2%となるよう添加することに変更する以外は、試験品1と同様の方法により、乳酸菌飲料を調製した。得られた乳酸菌飲料は、バナナ果汁を0.5%含有するものであり、これを試験品2とした。 Further, a lactic acid bacteria beverage was prepared by the same method as in Test Product 1 except that the aqueous dilution of concentrated banana juice (Brix17) was added to the medium so as to have a concentration of 2.2%. The obtained lactic acid bacteria beverage contained 0.5% of banana juice, and this was designated as Test Product 2.

また、さらに、製造例2で得られたバナナ抽出物(Brix17)を培地に2.2%となるよう添加することに変更する以外は、試験品1と同様の方法により、乳酸菌飲料を調製した。得られた乳酸菌飲料は、バナナ抽出物を0.5%含有するものであり、これを試験品3とした。 Further, a lactic acid bacteria beverage was prepared by the same method as in Test Product 1 except that the banana extract (Brix17) obtained in Production Example 2 was added to the medium so as to have a content of 2.2%. .. The obtained lactic acid bacteria beverage contained 0.5% of banana extract, which was designated as Test Product 3.

また、製造例3で得られた脱塩液(Brix12.3)を培地に6.1%となるよう添加することに変更する以外は、試験品1と同様の方法により、乳酸菌飲料を調製した。得られた乳酸菌飲料は、脱塩液を1.38%含有するものであり、これを試験品4とした。 Further, a lactic acid bacteria beverage was prepared by the same method as in Test Product 1 except that the desalting solution (Brix12.3) obtained in Production Example 3 was added to the medium so as to have a concentration of 6.1%. .. The obtained lactic acid bacteria beverage contained 1.38% of a desalting solution, and this was designated as Test Product 4.

一方、バナナの成分を含まないことに変更する以外は、試験品1と同様の方法により、乳酸菌飲料を調製し、これを試験品5とした。 On the other hand, a lactic acid bacterium beverage was prepared by the same method as in Test Product 1 except that the banana component was not contained, and this was designated as Test Product 5.

試験品1〜5の乳酸菌飲料を10℃、遮光環境下で保存し、保存開始直後と、保存後14日後の菌数より菌の生残率((d))を算出した。また、乳酸菌飲料中の各バナナ成分の含有量とそのBrixから、乳酸菌飲料中のバナナの成分由来のBrix((e))を求めた。結果を表2に示す。 The lactic acid bacteria beverages of Test Products 1 to 5 were stored at 10 ° C. in a light-shielded environment, and the survival rate ((d)) of the bacteria was calculated from the number of bacteria immediately after the start of storage and 14 days after storage. In addition, the Brix ((e)) derived from the banana component in the lactic acid bacteria beverage was determined from the content of each banana component in the lactic acid bacteria beverage and its Brix. The results are shown in Table 2.

Figure 0006770874
Figure 0006770874

試験品1〜4と試験品5の遮光保存14日後の菌の生残率を比較すると、試験品1〜4では、試験品5と同等か、それよりもさらに悪い生残率となっていた。このため、バナナ果汁の電気透析処理透過液、バナナ果汁、バナナ抽出物および脱塩液は、遮光保存中の菌数の低下を抑制する効果は奏さないことが明らかとなった。 Comparing the survival rates of the bacteria of the test products 1 to 4 and the test products 5 after 14 days of light-shielding storage, the survival rates of the test products 1 to 4 were equal to or worse than those of the test products 5. .. Therefore, it was clarified that the electrodialysis-treated permeate of banana juice, banana juice, banana extract and desalted solution do not have the effect of suppressing the decrease in the number of bacteria during light-shielded storage.

本発明の光照射時の乳酸菌抑制剤は、光照射下において、乳酸菌数の低下を抑制することができるものであるため、光にさらされる環境下での保存時に有用性が高いものである。特に、本発明の光照射時の乳酸菌数低下抑制剤としてバナナ抽出物の処理物やバナナ果汁の処理物を用いると、これらを添加した発酵乳製品はバナナの風味があまり感じられず、他の果汁等を添加することによって、好みの風味に調整することが可能である。従って、本発明の光照射時の乳酸菌数低下抑制剤は、様々な発酵乳製品に利用することができるものである。
以 上
Since the lactic acid bacterium inhibitor at the time of light irradiation of the present invention can suppress a decrease in the number of lactic acid bacteria under light irradiation, it is highly useful at the time of storage in an environment exposed to light. In particular, when a processed product of banana extract or a processed product of banana juice is used as an inhibitor of the decrease in the number of lactic acid bacteria during light irradiation of the present invention, the fermented dairy products to which these are added do not have much banana flavor and other By adding fruit juice or the like, it is possible to adjust the flavor to a liking. Therefore, the agent for suppressing a decrease in the number of lactic acid bacteria during light irradiation of the present invention can be used in various fermented dairy products.
that's all

Claims (6)

バナナ抽出物及び/又はバナナ果汁の透析処理液の分子量300Da以下の画分を有効成分とすることを特徴とする光照射時の乳酸菌数低下抑制剤。 An agent for suppressing a decrease in the number of lactic acid bacteria during light irradiation, which comprises a fraction having a molecular weight of 300 Da or less in a dialysis treatment solution of banana extract and / or banana juice as an active ingredient. 透析処理液が、電気透析処理液である請求項1記載の光照射時の乳酸菌数低下抑制剤。 The agent for suppressing a decrease in the number of lactic acid bacteria during light irradiation according to claim 1, wherein the dialysis treatment solution is an electrodialysis treatment solution. 請求項1又は2記載の光照射時の乳酸菌数低下抑制剤と、乳酸菌とを含有する発酵乳製品(但し、バナナ果汁を含有するものを除く)。 A fermented dairy product containing the lactic acid bacterium count decrease inhibitor during light irradiation according to claim 1 or 2 ( excluding those containing banana juice ). 乳を主原料とする培地で乳酸菌を培養して乳酸菌培養物を調製し、次いで、この乳酸菌培養物に、バナナ抽出物及び/又はバナナ果汁の透析処理液の分子量300Da以下の画分を配合することを特徴とする発酵乳製品の製造方法。 Lactic acid bacteria are cultivated in a medium containing milk as a main raw material to prepare a lactic acid bacterium culture, and then a fraction having a molecular weight of 300 Da or less of a banana extract and / or a dialysis treatment solution of banana juice is added to the lactic acid bacterium culture. A method for producing a fermented dairy product. 透析処理液が、電気透析処理液である請求項4記載の発酵乳製品の製造方法。 The method for producing a fermented dairy product according to claim 4, wherein the dialysis treatment liquid is an electrodialysis treatment liquid. バナナ抽出物及び/又はバナナ果汁の透析処理液の分子量300Da以下の画分と、乳酸菌とを含有する発酵乳製品(但し、バナナ果汁を含有するものを除く)。 Fermented dairy products containing a fraction of a banana extract and / or a dialysis treatment solution of banana juice having a molecular weight of 300 Da or less and lactic acid bacteria ( excluding those containing banana juice ).
JP2016219089A 2016-11-09 2016-11-09 Lactic acid bacteria count reduction inhibitor and fermented dairy products containing it Active JP6770874B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016219089A JP6770874B2 (en) 2016-11-09 2016-11-09 Lactic acid bacteria count reduction inhibitor and fermented dairy products containing it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016219089A JP6770874B2 (en) 2016-11-09 2016-11-09 Lactic acid bacteria count reduction inhibitor and fermented dairy products containing it

Publications (2)

Publication Number Publication Date
JP2018074950A JP2018074950A (en) 2018-05-17
JP6770874B2 true JP6770874B2 (en) 2020-10-21

Family

ID=62148586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016219089A Active JP6770874B2 (en) 2016-11-09 2016-11-09 Lactic acid bacteria count reduction inhibitor and fermented dairy products containing it

Country Status (1)

Country Link
JP (1) JP6770874B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230166709A (en) * 2022-05-31 2023-12-07 순천대학교 산학협력단 Banans Fermented Beverage and method of preparing therefor

Also Published As

Publication number Publication date
JP2018074950A (en) 2018-05-17

Similar Documents

Publication Publication Date Title
JP4739335B2 (en) Lactic acid bacteria fermented product and fermented milk food containing the same
JP4746615B2 (en) Bifidobacterium-containing fermented food and method for producing the same
KR102675263B1 (en) Cheomcha extract essence and its uses
JP5654824B2 (en) Fermented food and method for producing the same
JP2015006161A (en) Composition for lactic acid bacteria proliferation
JP6770874B2 (en) Lactic acid bacteria count reduction inhibitor and fermented dairy products containing it
KR102021802B1 (en) Lactobacillus culture and method for producing same
JP5329924B2 (en) Fermented food containing lactic acid bacteria and method for producing the same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180727

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190611

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190809

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200204

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200915

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200928

R151 Written notification of patent or utility model registration

Ref document number: 6770874

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151